MDXH
MDxHealth S.A.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-8.48
P/S
0.98
EV/EBITDA
-27.67
DCF Value
$-61.32
FCF Yield
-11.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
59.7%
Operating Margin
-14.3%
Net Margin
-31.1%
ROE
516.6%
ROA
-22.7%
ROIC
-14.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $54.7M | $-18.8M | $-0.37 |
| FY 2025 | $107.9M | $-33.5M | $-0.67 |
| Q2 2025 | $53.2M | $-14.7M | $-0.30 |
| Q4 2024 | $48.1M | $-18.0M | $-0.38 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
BE
Exchange
NASDAQ
Beta
0.38
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.